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Abstract
With the increase in demand for biopharmaceutical products, industries have realised the need to scale up their manufacturing from laboratory-
based processes to financially viable production processes. In this context, biopharmaceutical manufacturers are increasingly using simulation-
based approaches to gain transparency of their current production system and to assist with designing improved systems. This paper discusses
the application of Discrete Event Simulation (DES) and its ability to model the various scenarios for dynamic decision making in
biopharmaceutical manufacturing sector. This paper further illustrates a methodology used to develop a simulation model for a
biopharmaceutical company, which is considering several capital investments to improve its manufacturing processes. A simulation model for a
subset of manufacturing activities was developed that facilitated ‘what-if’ scenario planning for a proposed process alternative. The simulation
model of the proposed manufacturing process has shown significant improvement over the current process in terms of throughout time
reduction, better resource utilisation, operating cost reduction, reduced bottlenecks etc. This visibility of the existing and proposed production
system assisted the company in identifying the potential capital and efficiency gains from the investments therefore demonstrating that DES
can be an effective tool for making more informed decisions. Furthermore, the paper also discusses the utilisation of DES models to develop a
number of bespoke productivity improvement tools for the company.
© 2015 The Authors. Published by Elsevier B.V.
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1. Introduction
EvaluatePharma World Preview consensus forecasts the
prescription drug sale to be $895 billion of which biological
products account to about 50%. [1]. With this increasing
demand, biopharmaceutical manufacturers are now looking at
scaling up their manufacturing processes to mass produce
biological products, especially Gene Therapy (GT) products.
GT is a new generation of biopharmaceutical drugs that are
targeted at treating genetic disorders as well as life threatening
conditions such as cancer. FDA (2013) defines GT as a
‘treatment process that introduces genetic material into a
DNA to replace faulty or missing genetic material, thus
treating a disease or abnormal medical condition’ [2]. Despite
their increasing popularity and promising nature, most of GT
products have long remained in clinical trial phases. With the
completion of clinical trials nearing the end, there is a definite
possibility for these drugs to be developed into commercially
available and effective GT products. However, unlike
conventional drugs that are mass produced, GT products are
novel/complex and hence offer unique challenges in product
development. Complex manufacturing processes [3], high
cost of production [4], high risk of clinical failure [5], strict
regulatory policies [6] are likely to affect the manufacturing
processes. GT companies considering expansion need to make
investment decisions under these uncertain conditions and
have to realise that the key to their commercial success lies in
optimal planning, efficient manufacturing and early
assessment of cost/benefits. Therefore, computer-aided
simulation tools are increasingly being used to capture the
dynamic behaviour of the current process and to experiment
with various process alternatives.
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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This paper presents a Discrete Event Simulation (DES)
model developed in Witness 13 visualising a subset of the GT
manufacturing processes in order to assess the impact of the
proposed investment decision involving a process alternative.
The model evaluates the alternatives in terms of
manufacturing time, cost, resources utilisation, bottlenecks,
and throughput. Section 2 & 3 of this paper provides a brief
overview of various modelling approaches and their relevance
to biopharmaceutical process modelling along with the
challenges in their adoption in GT industries. Section 3
outlines the methodology employed to develop a DES model
to support ‘what-if’ scenario planning along with a case study
from a biopharmaceutical company (Section 4).
2. Approaches in Biopharmaceutical process and business
modelling
Decision-making in drug development is increasingly
relying on tools that capture dynamic process data and
facilitate representation of technical/business aspects of drug
development. Fig. 1 illustrates the application of such tools in
various stages of biopharmaceutical drug development as
depicted by Ashouri (2001) [7]. Despite the range of
application, their utilisation is not as seamless in process
industries as it is in mature manufacturing industries such as
Automobile/Aerospace. This may be because the GT
industries are still developing their core technology and the
use of computer-aided tools in process planning and
optimising is a novelty [8]. Furthermore, Saraph (2001) [9]
regards biopharmaceutical as complex manufacturing
characterised by:
x Lack of well-defined processes with a mix of discrete and
continuous flows
x Intermediate quality control and assurance processes
between production stages
x Non-uniform batch sizes and buffer sizes that vary
significantly from stage to stage
x Highly uncertain production output due to shorter shelf-
life of products and higher rejection rates
x Limited standardisation/automation with manual handling
of materials
x Stringent regulations, adherence to Good Manufacturing
Practices (GMPs) creating further operational constraints
2.1. State of the art methodologies and tools
Despite the challenges, many researches have considered
computer-aided process design, simulation, and scheduling
tools to enhance the understanding of bioprocesses and to
develop test cases for evaluation [10, 11]. Usage of these
computer-aided tools in the biopharmaceutical industry falls
broadly into four categories as depicted in Fig. 2. Although
this classification distinguishes one methodology from
another, in practice, most of the tools developed for industries
are a combination of one or more of these methods.
Mathematical programming is the oldest and traditional
method involves building mathematical relationships between
variables to technically represent the unit operations. For
example, mass balance equations created using spreadsheets
or general-purpose simulators such as SPEEDUP by Aspen
Technology (12), Matlab (13), and Labview by National
Instruments (14) are used to model unit operations in
biopharmaceutical manufacturing. These methodologies do
not have the capability to visualise unit operations in real
time. Therefore, mathematical modelling methods have
slowly evolved to use graphical user interfaces. Hierarchical
modelling approaches developed by Farid et al [15] uses
Object Oriented Programming (OOP) implemented in a
graphical simulation tool (ReThink) to simulate the key
activities in manufacturing such as resource utilisation and
cost. This method combines both process modelling using
mass balance methods for plant design and capacity
management, and business modelling using techniques such
as investment appraisal, risk evaluation, and production
planning.
Karri et al [16] has also applied the OOP methodology to
model not just the key tasks but also other activities in the
manufacturing stage. Furthermore, in another study, Lim et al.
[17] extends this hierarchical approach to include additional
tasks such as QA/QC and documentation using a DES based
tool (ExtendSim). Whilst, mathematical programming and
DES methods are deterministic, Rajapakse et al. [18] has
developed a tool to model the uncertainties in
biopharmaceutical product portfolio management to predict
the outcome of various development strategies using
techniques such as Monte Carlo Simulation and Sensitivity
Analysis. It quantifies the outputs in the form of economic
metrics such as Net Present Value (NPV) to support decision-
making. Application of stand-alone DES packages also allow
stochastic and dynamic modelling of biopharmaceutical
processes/systems aimed for capacity planning, scheduling,
debottlenecking, and water minimisation [8, 9]. Another tool
developed by Sharda and Bury [19] has shown the potential
application of DES model (built in ExtendSim) in the
maintenance stage. On the other hand, optimisation
methodologies employed by Petries [20] uses SuperPro
Designer simulation package to account for batch process
simulation rather than unit operation simulation.
Fig. 1. Computer-aided tools in biopharmaceutical product development (adapted from Ashouri (2001) [7])
Idea Generation Stage
• Project screening and
selection
Process Design Stage
• Process improvements and
optimisation
• Cost Benefit evaluation of complex
processes
• Environmental impact assessment
Facility Design and
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• Capacity evaluation
•Manufacturing strategy
selection
• Capital Expenditure evaluation
Manufacturing Stage
• Process Optimisation
•Optimum scheduling
•Debottlenecking
41 Madhu Sachidananda et al. /  Procedia CIRP  49 ( 2016 )  39 – 44 
Fig. 2. Classification of Simulation Methodologies
The tool developed can be used to evaluate resource
utilisation, material balances, environmental emissions, cycle
time analysis, and scheduling problems to debottleneck and
optimise batch processes. Additionally, several bespoke
spreadsheet-based tools are widely developed and used in
industries to address specific needs. One tool of relevance is
BioSolve [21] by Biopharm Services Ltd. It is a stand-alone
Microsoft-Excel Spreadsheet based analytical tool particularly
targeted at modelling the manufacturing processes to estimate
the performance and costs of the existing system to compare it
with a future system.
3. Scope for Research Work
Given the range and capacity of these modelling
methodologies/tools, the selection of a particular or a
combination of these techniques is based on the type of
solution required and also the application area (whether
modelling a unit process or overall business operation).
Although very comprehensive, mathematical programming
methods are most likely to be used for mass balancing of
chemical processes in unit operations, and on the other hand
DES is more suitable for modelling discrete and dynamic
systems to visualise the flow of entities and resources (activity
scheduling and resource utilisation). Also, the mass balancing
methodologies have shown limited applications when
considering parallel processing or when there are too many
input parameters [22].
Alternatively spreadsheet-based tools/solutions are very
simplistic and do not score well in the areas of dynamic
modelling and visualisation of processes which is a
prerequisite for most simulation modelling. A spreadsheet-
based model may not consider complex aspects of simulation
such as: parameters that change over time, restrictions on
various resources, queuing of products, variability in
arrival/processing etc. In order to account for such variability
and discrepancies, average values are used in spreadsheet
models which are most likely to result in deterministic
outcomes that are again averaged out. Therefore the final data
or results are far from the actual outcome. On the other hand,
DES offers flexibility to model various system constraints and
their interaction with each other in greater detail. In addition
DES software accounts for various restraints on the resources
(setups, equipment breakdown, skill levels of a worker, shift
patterns etc.) to be modelled in order to visualise the knock-on
effect it may have on other downstream processes. Therefore,
as highlighted in the review:
1. There is a need for a simplistic approach to dynamically
model the biopharmaceutical manufacturing unit
operations and to utilise the simulation output to support
business decisions.
2. DES based tools provide the flexibility to model non-
linearity, uncertainties that would have been time
consuming and inaccurate if any other approaches were
considered.
In light of this, a methodology for the development of a
DES model is presented in this paper along with a proposed
framework for an investment appraisal decision support tool.
4. DES Modelling Approach
As established in the previous section, simulation in
biopharmaceutical industry, although not significantly
developed, is very crucial since the effects of very small
process variations having much greater impacts on the system
can be visualised. Also modelling for biopharmaceutical
presents its own challenges because of lack of standardisation
(variable time, variable titre, variable rejection etc.) and high
uncertainties. Hence simulation approaches based on discrete
events offer flexibility to capture the dynamic (where model
changes over time) stochastic (include the impact of
uncertainty) processes of GT manufacturing. Witness 13
simulation package was used to develop the model. Witness
was chosen because of its ability to simulate both discrete and
continuous flows which is the characteristic of many process
industries including biopharmaceutical.
4.1. Modelling methodology
The challenges presented in simulating (see section 2)
biopharmaceutical manufacturing process required a specific
methodology to be defined for the DES model development
and is as shown in Fig. 3. Mapping the processes and
understanding the scope of the project is fundamental in
model development. A model can represent an individual
manufacturing stage/activity in the entire system or include a
range of activities within a system therefore it is essential to
define the modelling boundaries prior to model development.
Models at a higher level of abstraction only require
information related to the primary processes whereas a model
with a lower level of abstractness requires detailed
information that includes secondary processes information.
For example, costing, energy and water usage, waste
generation etc.).
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Fig. 3. Discrete Event Simulation Methodology
The next step in model development is to identify the
elements in the simulation engine that represent the
manufacturing system under study. Modelling elements such
as entities (elements that flow through the system), variables
(elements that change over time), attributes (the
characteristics of elements), resources (system assets,
machines, conveyors, labour, buffers) are determined. These
are essential to build the simulation logic and to establish
product and resource flows.
The data input into the model development determines the
accuracy of the simulation results. Therefore, the model is
built in several modules representing various unit operations
(illustrated in Fig. 4) to facilitate easier data collection
organization, and validation. Given the uncertain environment
characterized by both market and technical risks in GT
manufacturing, variables are defined to input data.
Additionally the flexibility to connect with an external file
enables dynamic import and export of simulation data to and
from the simulation software. Within the simulation engine,
input data can be categorised into three types: (i) Product
Flow data (ii) Process Schedule data (iii) System Capacity
data. The continuous and discrete flow of products require
product flows represented as moving parts/entities per unit
time as well as flowrates/volumes for fluids. Process specific
data includes data pertaining to activities such as process
times, batch process consideration, input and output rules,
resource schedules, clean in place schedules etc. whilst the
system capacity data includes data pertaining to the capacity
of the system such as, buffer capacity, number of runs, run
length, costing data etc. In order to address the objectives
defined in the initial stages of model development, a number
of performance parameters were defined at the overall process
and unit operation level (see Table 1).
4.2. Cost Benefit Analysis
Integral to this study was the development of an
Investment Appraisal tool for Cost Benefit Analysis. The
efficiency benefits in terms of time saving, better operator
utilization, reduced waste achieved in the new process
(visualized in the simulation model) can be utilized in
evaluating the benefits of the new process. The open
architecture of the Witness simulation model permits
assessment of various production alternatives by comparing
their performance parameters.
Table 1. Performance Parameters
Level Performance Parameter
Project Campaign/Subrun throughput time
Rejections
Resource Cost
Process Process Time
Number of Operators
Operator Utilization
MSC Utilization
Operation Queuing Times
Operation Time
Reagents Used (vol)
Reagents Wasted (vol)
Cost of Reagents
5. Case Study
The case study details a DES model developed for a subset
of the GT manufacturing process at a biopharmaceutical
company. The process considered in this cases study is
preparing the media used in cell culture. Media is used in
various stages of production (growing cells and viral vectors,
recovering viral vectors/harvesting, purification) and is
prepared by measuring and adding four types of reagents to it
in batches. The current process and a future state is modelled
using the methodology discussed in Section 4.
5.1. Problem Definition
Some of the critical issues noted in the current
manufacturing process are as listed:
Fig. 4. DES framework with Excel integration
Identify scope and assumptions
Define simulation objectives
Determine modelling entities, variables, attributes,
resources
Determine modelling constraints (process times, CIPs,
changeovers, etc.)
Collect simulation data
Define key performance parameters
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x Longer processing times (batch production leading to
multiple grade transitions in the production plant)
x Labour intensive & manual handling leading to increased
risk of unwanted errors and occasional microbial
contamination
x Increased number of pharma containers requiring more
storage space
x Risk of inconsistent cell distribution and concentration
within unit operations
x Bottlenecks in terms of personnel and equipment
In order to address these issues, the company proposed a
new technology to prepare media in bulk instead of multiple
small batches which requires significant changes in the way of
working within the existing manufacturing facility. In order to
visualize the proposed process change a simulation model was
developed that enabled what-if scenario planning.
5.2. Simulation Objectives
Based on the current and proposed manufacturing
processes, the following objectives were defined:
x Model current state (batch process with aliquots and
pharma containers)
x Estimate current process time /cost for media preparation
x Model proposed state (pallet tanks with bags reagent
addition without dividing into pharma containers)
x Compare the key performance parameters for current and
proposed state (as identified in Table 1)
x Quantify the impact of capital investment
x Identify further improvement opportunities
5.3. Data Collection
As highlighted in section 3, the data collection was for
three levels: product, processes, and system. A range of
sources such as manufacturing records, historical data,
literature, etc. were used to obtain default values. Three
workshops, each with duration of 3 hrs, with the project
management team were held to understand the initial
requirements. Additionally, the visit to the clean rooms gave
an insight into the actual media manufacturing process. Senior
biotechnologists and process improvement experts were
consulted to gather process/cost data and validate the
modelling assumptions at every stage.
5.4. Simulation Model Development
The model for the entire media preparation process was
built in modules consisting of five unit operations: (1) Media
division, (2) Reagent 1 addition, (3) Reagent 2 addition, (4)
Reagent 3 addition, and (4) Reagent 4 addition as depicted in
Fig. 5. These modules were developed and validated
independently prior to their integration. In the current
manufacturing process, the pharma containers move from one
safety cabinet to another in batches where the reagents are
manually added into the pharma containers. Fig. 5 also
illustrates the key variables and constraints defined to develop
the simulation model in Witness 13. In the proposed
manufacturing process, the reagents are sequentially added to
the media contained in a large pallet tank which substantially
reduced the number of processing steps thereby significantly
reducing the need for manual handling. Fig. 6 illustrates the
conceptual simulation model of the proposed process.
6. Simulation Results
The simulation models developed in Witness indicated
considerable improvements in the proposed process over the
existing process. The proposed system requires transfer of
reagents directly into the tanks and eliminates repetitive
processes such as pipetting each reagents, handling multiple
pharma containers, and sterilization. The three main
performance parameters that were of interest to the company
were (1) Process time (2) No. of Operators (3) Operator
Utilisation (summarized in Table 2). The existing process
took about 95 minutes to prepare a batch of media whilst the
proposed process required only 45 mins. The proposed
process showed about 50% reduction in throughput time
releasing the safety cabinets and other shared resources.
Fig. 5. Conceptual model of the current process
Fig. 6. Conceptual model of the proposed process
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Batch_Size
Volume
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Queue_Time
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Table 2. Key Performance Parameters for current and proposed media
preparation process
Key Process
Parameter
Current Media
Preparation
Proposed Media
Preparation
Process Time 95 mins per subrun 45 mins per subrun
No. of Operators 3 per subrun 2 per subrun
Operator Utilisation 60% per subrun 85% per subrun
Furthermore, the operators required in the proposed
process were reduced from three to one along with a 25%
increase in operator utilization. The model developed and the
result obtained for the current process is reflective of the real
system and was verified by comparing simulation outputs
with the manufacturing records. The simulation results for
the proposed process were utilized in an Investment Appraisal
tool to quantify the efficiency benefits. The validation process
included workshops with suppliers and project management
teams to evaluate costs/benefits of the proposed process. The
figures obtained were very close to the initial estimates
provided by the project management.
7. Conclusion
The study has highlighted the value of applying computer-
aided tools in decision-making for biopharmaceutical (and
other) manufacturing. Whilst simulation techniques are
widely utilized to address various operational issues, there is
an opportunity for their increased and targeted application in
biopharmaceutical process modelling.
This paper has presented a Discrete Event Simulation
(DES) model for a subset of GT manufacturing process that
was developed in Witness. The systematic methodology
adopted in this paper allowed modelling of both discrete and
continuous flow of elements which is intrinsic to GT
manufacturing. Moreover, the modular approach and the
integration of the simulation engine with an external .csv file
confer maximum flexibility for ‘what-if’ scenario planning
and allow dynamic assessment of various process alternatives.
The DES model developed for the company provided a
sense of reality into the existing and proposed process flow
enabling focus groups to easily map the specific areas of
improvement and potential benefits in terms of cost, risk,
time, material, manpower etc. Additionally the results from
the simulation model were used as support material in
explaining and defending decisions to various stakeholders,
which has demonstrated a streamlined approach to business
decision-making. The quantification of parameters in DES
model has also been utilized in an investment appraisal tool to
facilitate rational and objective evaluation of the proposed
investment decisions.
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